Heart Disease News and Research

Latest Heart Disease News and Research

Reverse Medical closes Series-B private equity financing

Reverse Medical Corporation announced today the closing of their Series-B private equity financing. The Company raised $14 million from new investors Wexford Capital, Getz Bros., BioStar Ventures, Early Stage Partners and Emergent Medical Partners.

31 Mar 2010

Asclera injection receives FDA approval

The U.S. Food and Drug Administration today approved Asclera (polidocanol) injection for the treatment of small types of abnormally swollen or twisted veins called varicose veins.

31 Mar 2010

Ascent Therapeutics is now Anchor Therapeutics

Ascent Therapeutics announced today that it has adopted a new name — Anchor Therapeutics. Anchor Therapeutics reflects the Company's core technology and its commitment to building solid, dependable value for patients, partners and investors via its proprietary platform technology.

30 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Campbell Soup honored for commitment to food allergy safety, awareness and education

Campbell Soup Company was recently honored by the Food Allergy and Anaphylaxis Network for its commitment to food allergy safety, awareness and education.

30 Mar 2010

Healthy hearts: Interventions needed to keep people exercising following cardiac rehabilitation programs

Researchers from the Frances Payne Bolton School of Nursing at Case Western Reserve University found that one year after 248 individuals completed a 12-week cardiac rehabilitation program following a heart attack, bypass surgery or angioplasty, only 37% exercised three times a week to keep their hearts healthy.

30 Mar 2010

Chocolate can lower blood pressure and reduce risk of heart disease: Study

Easter eggs and other chocolate may be good for you - at least in small quantities and preferably if it's dark chocolate - according to research that shows just one small square of chocolate a day can lower your blood pressure and reduce your risk of heart disease. The study is published online today (Wednesday 31 March) in the European Heart Journal.

30 Mar 2010

Preventive health care researchers meet to outline vision for evidence-based prevention in health care

Leading preventive health care researchers, physicians and executives assembled at U.S. Preventive Medicine® Friday to outline their vision for advancing evidence-based prevention in health care.

30 Mar 2010

Gout incidence lower in women than men: Study

Researchers from Boston University School of Medicine found that women with serum uric acid levels over 5 mg/dl had a significantly lower risk of developing gout than men. This study, the first to examine the relationship between uric acid levels and gout risk in women, also evaluated purported risk factors for gout and found that increasing age, obesity, hypertension, alcohol use, and diuretic use to be among leading contributors for women.

30 Mar 2010

Plaques in blood vessels may break by overproducing protein-digesting enzymes

University of Washington (UW) researchers have gathered evidence that dangerous plaques in blood vessels can rupture by overproducing protein-digesting enzymes. Plaques are fat-laden rough spots in the otherwise smooth walls of arteries. When a plaque ruptures, blood accumulates inside of it, a process known as plaque hemorrhage. The plaque enlarges and artery-blocking clots can form. If the flow of oxygen-rich blood is restricted, a heart attack, stroke, or damage to other organs can occur.

30 Mar 2010

New DNA test to detect Lyme disease spirochete infection

Many of the more than 30,000 people a year in the United States with suspected cases of Lyme disease spirochete (bacterial) infection can now take a DNA test developed by a Connecticut scientist/physician and his team that can quickly determine if they test positive for Lyme spirochetes in their blood.

30 Mar 2010

Few pregnant women meet physical activity guidelines set by health officials: Study

Fewer than 1 in 4 pregnant women meet physical activity guidelines set by doctors and health officials, according to a University of North Carolina at Chapel Hill study.

30 Mar 2010

Systemic treatment of microRNA therapeutic targeting miR-10b inhibits breast cancer metastasis

Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.

30 Mar 2010

ASA encourages spreading awareness about Doctors Day 2010

The American Society of Anesthesiologists joins communities across the United States today to recognize Doctors Day 2010, a day with a special tie to anesthesiology.

30 Mar 2010

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation.

30 Mar 2010

CEO Roundtable on Cancer announces Gold Standard accreditation for Susan G. Komen for the Cure

Susan G. Komen for the Cure®, the world's largest breast cancer organization, has received CEO Cancer Gold Standard™ accreditation, recognizing the organization's commitment to reducing the risk of cancer for its employees and their families by promoting healthy lifestyle choices, by encouraging early detection through cancer screenings, and by ensuring access to quality treatment.

30 Mar 2010

Higher levels of CRP associated with brain changes: Study

New research shows that a high level of C-reactive protein, a marker for inflammation in the blood, is associated with brain changes that are linked to problems with executive thinking skills. The study is published in the March 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

30 Mar 2010

Rite Aid, AAAAI team up to offer guides to allergy sufferers

Rite Aid and the American Academy of Allergy, Asthma & Immunology are again teaming up this spring to help allergy sufferers with free allergy guides available now in nearly 4,800 Rite Aid stores nationwide and online at www.riteaid.com.

30 Mar 2010

Royal Philips Electronics introduces InnerCool RTx Endovascular System

Royal Philips Electronics announced today its launch of the Philips InnerCool RTx Endovascular System for cooling and warming, which provides advanced whole body temperature modulation therapy in a closed-loop system from the inside out. The InnerCool RTx is a high-performance system that can rapidly raise and lower the body temperature of certain non-paralyzed, awake patients of all sizes in the intensive care setting.

From Philips Healthcare 30 Mar 2010

LCT receives approval for New Zealand Phase II human trial of DIABECELL

Living Cell Technologies Limited, a global company pioneering the development of a cell implant to treat diabetes, today announced that it has received approval to advance to the next phase of its New Zealand Phase II human clinical trial with its groundbreaking DIABECELL®. The approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first four patients to receive its DIABACELL® implants.

30 Mar 2010